Prognosefaktoren und adjuvante Chemotherapie-Schemata in der Gruppe sporadischer, tripel negativer Mammakarzinompatientinnen
Georg Pfeiler(Medical University of Vienna), Christian F. Singer(Comprehensive Cancer Center Vienna), C. Dittrich(Kaiser-Franz-Josef-Spital), D Jahn-Kuch(University of Vienna), Robert Königsberg(Kaiser-Franz-Josef-Spital), C Natter(University of Vienna), Robert Zeillinger(Comprehensive Cancer Center Vienna), Miroslav Hudec(University of Vienna), Rafał Kurzawa(University of Vienna)
Cited by 0
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
|Annals of Oncology|2022|461
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
|Annals of Oncology|2013|403